# Ind-Swift Laboratories Limited (INDSWFTLAB)

> INDSWFTLAB closed at ₹368.20 on 30 Oct 2026, trailing P/E 38.3, market cap ₹3,202 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Ind-Swift Laboratories Limited (NSE: INDSWFTLAB) closed at ₹368.20 on 30 Oct 2026, +263.3% over one year, against a 52-week range of ₹87.15 – ₹426.60.

In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹240 cr and net profit of ₹34 cr, a 14.2% net margin; revenue grew 57.5% and profit grew 319.4% year on year.

On four consecutive filed quarters its trailing P/E is 38.3; since 12 Aug 2025 its own P/E has ranged from 3.0 to 60.6 (median 4.7), and today's reading is higher than 71% of those 298 trading days.

From the balance sheet dated 30 Sept 2026: return on equity 9.3%, ROCE 11.9%, debt-to-equity 0.01, Piotroski F-score 5 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 56% of 64 sector peers; PBT margin higher than 53% of 64 sector peers; ROE higher than 23% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹368.20 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -8.2% / +168.0% / +263.3% |
| 52-week low – high | ₹87.15 – ₹426.60 |
| Market capitalisation | ₹3,202 cr |
| Trailing P/E | 38.3 |
| Price / book | 2.17 |
| EV / EBITDA | 21.1 |
| Earnings yield | 2.6% |
| TTM EPS | ₹9.61 |
| TTM net profit | ₹84 cr |
| Quarter revenue | ₹240 cr |
| Quarter net profit | ₹34 cr |
| Net margin | 14.2% |
| Revenue growth (YoY) | +57.5% |
| Profit growth (YoY) | +319.4% |
| Return on equity | 9.3% |
| ROCE | 11.9% |
| Debt / equity | 0.01 |
| Current ratio | 3.90 |
| Free cash flow | ₹-102 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹21.7 cr |

## Questions

### What is the P/E ratio of Ind-Swift Laboratories Limited?

Ind-Swift Laboratories Limited's trailing P/E is 38.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 12 Aug 2025 its P/E has ranged 3.0–60.6.

### What were Ind-Swift Laboratories Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Ind-Swift Laboratories Limited reported revenue of ₹240 cr and net profit of ₹34 cr (consolidated), filed with the exchange on 29 Oct 2026.

### What is Ind-Swift Laboratories Limited's ROE?

Return on equity is 9.3% based on the balance sheet dated 30 Sept 2026.

### Does Ind-Swift Laboratories Limited have debt?

Debt-to-equity is 0.01 on the balance sheet dated 30 Sept 2026.

### What is INDSWFTLAB's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, INDSWFTLAB traded between ₹87.15 and ₹426.60.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/INDSWFTLAB

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._